NEUTRAL / RISK-OFF SELECTIVE Monday's AI repair and flat U.S. futures temper—but do not cancel—the warning from $86.63 WTI, a 4.75% U.S. 10-year yield and weak small-cap/European breadth.
Generated 08:30:33 CEST (Europe/Rome) / 06:30:33 UTC. Data cutoff about 08:22 CEST. Asian values are Sep. 1 latest/near-close; U.S. futures are overnight indications; U.S. and European cash figures are Aug. 31 closes because 08:30 Italy precedes the European opening print and U.S. cash trading/many U.S. releases.
The official 10-year yield rose 2 bp to 4.75%, WTI added another 1.01% overnight to $86.63, and Reuters reported that higher energy prices were deepening the bond selloff. The combination raises the discount-rate hurdle for long-duration themes. Treasury · Reuters discovery · WTI
NVDA +1.48%, AVGO +0.42%, VRT +0.64% and CRM +0.60% rose while the S&P and Russell fell. CRDO diverged at −2.82% before tonight's earnings. Monday was a selective repair, not a confirmed index-wide risk-on turn. NVDA · CRDO
Nasdaq's live calendar lists CRDO after Tuesday's close and AVGO after Wednesday's close. Those are the nearest direct tests for AI connectivity, custom silicon and networking. Consensus fields are vendor estimates—not company guidance. Sep. 1 calendar · Sep. 2 calendar
Risk class: mega-cap semiconductor; high expectations/post-earnings volatility. Classification: repair continuation. Applicable horizon: day trade and 1–4 week swing; 3–12+ months only with sustained growth/margins/FCF. Direction remains uncertain.
Thesis/catalyst: Monday $220.78, +1.48%, recovered $220 after Friday's selloff; CRDO/AVGO results are ecosystem catalysts.
Evidence / counterargument: company reported exceptional revenue growth and strong guidance, and price outperformed Monday. Counter: Monday volume 124.3M was below the prior five-session 186.3M average, $221.30 capped the day, and 10Y reached 4.75%.
Entry/confirmation: require hold above $220 and break/close above $221.30 with semiconductor breadth; stronger confirmation above $225. Invalidation/downside: close below $216.20; $210–214 is the next reference zone and gaps can bypass stops. Key risks: China/export controls, valuation, margins, customer/capex concentration, rates and event read-through. price/volume
Risk class: large-cap enterprise cloud; post-earnings gap/high near-term volatility. Classification: relative-strength continuation. Applicable horizon: day trade/1–4 week swing; 3–12+ months requires recurring-growth and FCF review. Direction uncertain.
Thesis/catalyst: $257.54, +0.60%, held most of last week's earnings gap while major indices fell; this week's cloud earnings test software breadth.
Evidence / counterargument: three closes near/above $252 support relative strength. Counter: Monday rejected $262.28, volume 22.5M was below the prior five-session 24.9M average, and the gap remains vulnerable.
Entry/confirmation: stable $254–258 base then break above $262.28 with software breadth. Invalidation/downside: close below $249; a gap fill toward $230 is possible. Key risks: rates, valuation, competition, execution, AI monetization quality and post-earnings reversal. price/volume
Risk class: newly listed de-SPAC quantum; extreme price-discovery/liquidity risk. Classification: avoid chasing; bearish only after confirmation. Applicable horizon: day observation; 1–4 weeks wait for structure; no 3–12+ month call without financial evidence. Direction highly uncertain; short loss is unlimited.
Thesis/catalyst: Monday $17.30, −9.47%, after trading $17.30–24.69; listing mechanics remain the only verified catalyst here.
Evidence / counterargument: price closed at the session low on 2.01M shares, still more than twice the prior five-session average distorted by debut volume. Counter: float-driven momentum can reverse violently and future neutral-atom milestones may add value.
Entry/confirmation: no blind short; bearish only below $17 followed by a failed reclaim. Avoid is preferred. Invalidation/downside: bearish view invalid above $20.10 on sustained volume. Key risks: unknown effective float here, halts, warrants, dilution, squeeze and minimal chart history; borrow/fees not sourced. price · SEC
Risk class: mega-cap pharma; valuation plus clinical/regulatory event risk. Classification: avoid/underweight tactically, not an immediate short. Applicable horizon: 1–4 week wait; 3–12+ months only after franchise valuation and full data review. Direction uncertain; short loss is unlimited.
Thesis/catalyst: Monday $1,156.73, −1.52%, closed below prior $1,162.93 low as the peptide tape weakened; TRIUMPH-2 statistics remain unposted.
Evidence / counterargument: four-session decline from $1,233.66 and above-average Monday volume weaken trend. Counter: the obesity franchise is established and a favorable verified readout can gap shares higher.
Entry/confirmation: avoid until reclaim above $1,180 with healthcare-relative strength; bearish continuation requires close below $1,147. Invalidation/downside: tactical avoid expires above $1,190; bearish downside reference $1,100, not a forecast. Key risks: unknown trial statistics, safety/discontinuation, reimbursement, competition, manufacturing and valuation. price · trial
No third bullish or bearish idea: flat overnight futures, elevated oil/yields and imminent earnings binaries do not justify filling quotas. Waiting is a position.
| Ticker / exchange / risk | Classification & applicable horizon | Thesis/catalyst; evidence & counterargument | Entry/confirmation; invalidation/downside; key risks | C / R / O |
|---|---|---|---|---|
| Watch AVGO Nasdaq · mega-cap; event-gap, leverage and concentration risk | Direction uncertain; event watch. Day/swing only after Sep. 2 price discovery; 3–12+ months on guidance, margins and FCF. | $370.34, +0.42%; results are the key custom-silicon/networking read-through. Counter: high expectations; Nasdaq's $2.83 EPS is vendor consensus, not guidance. | Confirm post-report base above $376.59; below $365.35 weakens, with $355 reference. Risks: gap, rates, customer concentration, integration/leverage. | 82 / 97 / 64 |
| Watch CRDO Nasdaq · high-beta connectivity; event gap/liquidity risk | Direction uncertain; earnings watch. Day/1–4 weeks only after tonight's price discovery; long term on revenue, concentration and FCF. | $226.19, −2.82% on 4.26M versus 3.38M five-prior average; event can test AI connectivity demand. Counter: strong demand may overwhelm the weak setup. | No pre-event entry; require base/reclaim above $238.40. Below $222.91 weakens; gaps may bypass levels. Valuation, customer concentration, supply and rates. | 78 / 99 / 59 |
| Watch VRT NYSE · large-cap/high-beta AI power and cooling | Direction uncertain; repair watch. 1–4 week swing after confirmation; 3–12+ months on backlog, margins and FCF. | $258.72, +0.64%, but below Thursday's $269.28. Structural data-center power demand is the thesis; counter: no technical repair yet. | Confirm above $261.79 then $270; below $254.91 invalidates bounce, with $245 reference. Risks: capex timing, execution, valuation, rates and inputs. | 75 / 88 / 50 |
| Watch IONQ NYSE · speculative quantum; extreme duration/dilution risk | Direction uncertain; avoid-to-watch. Day/swing only above resistance; 3–12+ months requires commercial/unit-economics proof. | $39.31, +0.28% on unusually high 38.6M volume, but below Friday's $41.92 high. Counter: contract/hardware news can reverse it sharply. | Confirm above $40.55 then $42.94; below $38.43 weakens. Risks: cash burn, dilution, architecture, rates, volatility and squeeze; borrow/fees unknown. | 72 / 98 / 44 |
| Watch VKTX Nasdaq · small-cap biotech; high binary/dilution risk | Direction uncertain; evidence watch. No day chase; 1–4 week base only; 3–12+ months requires full clinical, safety, runway and regulatory review. | $32.78, +1.93%, but below Thursday's $33.86 and no new verified clinical catalyst. Counter: strong peptide data/partnership can create upside. | Confirm above $33.86 then $34.39; below $31.70 invalidates bounce, $30 reference. Risks: endpoint statistics, tolerability, cash runway not refreshed here, dilution, competition and regulatory path. | 63 / 94 / 47 |
C / R / O = Thesis Confidence / Risk / Opportunity. Confidence measures evidence quality, never guaranteed outcome probability.
Bias: neutral-to-defensive; use only confirmed NVDA/CRM breaks and avoid pre-earnings CRDO bets or blind PSQL shorts.
Biggest risk: oil/rate headlines and event gaps. Invalidation: caution eases if WTI reverses and semis/Russell advance with volume; worsens if ES loses Monday's range while yields rise.
Bias: selective AI repair, high cash through earnings and toward FOMC; quantum and peptide names need evidence, not narrative.
Biggest risk: energy-driven inflation plus expectation saturation. Invalidation: broad small-cap/semiconductor participation and a falling 10Y upgrade risk appetite.
Bias: favor profitable AI infrastructure after valuation/FCF work; demand commercial proof in quantum and full statistics, runway and regulatory evidence in biotech.
Biggest risk: persistent inflation, capex digestion, dilution or failed endpoints. Invalidation: durable disinflation plus verified order and FCF acceleration supports more duration exposure.